USE OF BETABLOCKERS IN THE TREATMENT OF INFANTILE HEMANGIOMA
DOI:
https://doi.org/10.47820/recima21.v4i8.3731Keywords:
Infantile hemangioma, propranolol, pediatrics, beta-blockersAbstract
Introduction: Infantile hemangiomas (IHs) are common benign vascular tumors in children. Historical and current treatment options include medical therapy, surgical resection, laser therapy or direct intralesional steroid injections. Objective: To group the main beta-blockers used in the treatment of infantile hemangioma and address their efficacy and safety. Methodology: Based on all the steps adopted, the guiding question defined was: "Is the use of beta-blockers in patients with infantile hemangioma, when compared to the use of placebo or other drugs, effective in resolving or reducing lesions?". Initially, 220 studies were found. After applying the search criteria, seven articles were chosen to compose the literature review. Results and discussion: it was observed that beta-blockers are widely used in the treatment of IHs, being mainly effective in the early and initial proliferative phases. The most commonly used beta-blocker is propranolol, but in cases of sensitivity or serious adverse events, timolol, atenolol, carteolol and betaxolol can be used, both in topical and oral presentation. Joint therapy with two beta-blockers has also been shown to be effective in resolving His. Conclusion: The use of beta-blockers in the treatment of infantile hemangioma is beneficial to patients, being safe and effective, and presenting little or no systemic side effects.
Downloads
References
DeHart A, Richter G. Hemangioma: Recent Advances. F1000Res. 2019 Nov 18;8:F1000 Faculty Rev-1926. doi: 10.12688/f1000research.20152.1. PMID: 31807282; PMCID: PMC6871355.
Castrén E, Salminen P, Vikkula M, et al.: Inheritance Patterns of Infantile Hemangioma. Pediatrics. 2016;138(5):pii: e20161623. 10.1542/peds.2016-1623
van Vugt LJ, van der Vleuten CJM, Flucke U, et al.: The utility of GLUT1 as a diagnostic marker in cutaneous vascular anomalies: A review of literature and recommendations for daily practice. Pathol Res Pract. 2017;213(6):591–7. 10.1016/j.prp.2017.04.023
Ainipully A, Narayanan SK, Vazhiyodan AP, et al.: Oral Propranolol in Infantile Hemangiomas: Analysis of Factors that Affect the Outcome. J Indian Assoc Pediatr Surg. 2019;24(3):170–175. 10.4103/jiaps.JIAPS_12_18
Poulose D, Lote S, Mahajan A, Gogineni JM. Nonselective Beta-Blockers for the Efficacious Healing of Ulcerated Infantile Hemangiomas in Unusual Locations of Two Female Infants. Cureus. 2021 Jul 28;13(7):e16683. doi: 10.7759/cureus.16683. PMID: 34462702; PMCID: PMC8389862.
Silva, M. E. da, Silva, W. M. da, Silva, G. M. da, Souza, R. G. de, Santos, J. A. dos, Luz, M. K. S. da, Ferreira, M. D. F., Silva, T. M. L., Rocha, L. C. P. da, & Silva, C. A. de O. (2020). Manifestações neurológicas provocadas por COVID-19: uma revisão integrativa da literatura / Neurological manifestations caused by COVID-19: an integrative literature review. Brazilian Journal of Development, 6(7), 52155–52163. https://doi.org/10.34117/bjdv6n7-750
MENDES, Karina Dal Sasso; SILVEIRA, Renata Cristina de Campos Pereira; GALVÃO, Cristina Maria. Revisão integrativa: método de pesquisa para a incorporação de evidências na saúde e na enfermagem. Texto & contexto-enfermagem, v. 17, p. 758-764, 2008.
Sousa, Luís & Marques-Vieira, Cristina & Severino, Sandy & Antunes, Vanessa. (2017). Metodologia de Revisão Integrativa da Literatura em Enfermagem. Revista Investigação Enfermagem. 2. 17-26.
Rikihisa, N., Takatsuka, H., Suzuki, T., Shiko, Y., Kawasaki, Y., Hanawa, M., Ishii, I., & Mitsukawa, N. (2022). Efficacy and Safety of Propranolol Gel for Infantile Hemangioma: A Randomized, Double-Blind Study. Biological & pharmaceutical bulletin, 45(1), 42–50. https://doi.org/10.1248/bpb.b21-00500
Pope, E., Lara-Corrales, I., Sibbald, C., Liy-Wong, C., Kanigsberg, N., Drolet, B., & Ma, J. (2022). Noninferiority and Safety of Nadolol vs Propranolol in Infants With Infantile Hemangioma: A Randomized Clinical Trial. JAMA pediatrics, 176(1), 34–41. https://doi.org/10.1001/jamapediatrics.2021.4565
Ji, Y., Chen, S., Yang, K., Zhang, X., Zhou, J., Li, L., Xiang, B., Qiu, T., Dai, S., Jiang, X., Lu, G., Qiu, L., Kong, F., & Zhang, Y. (2021). Efficacy and Safety of Propranolol vs Atenolol in Infants With Problematic Infantile Hemangiomas: A Randomized Clinical Trial. JAMA otolaryngology-- head & neck surgery, 147(7), 599–607. https://doi.org/10.1001/jamaoto.2021.0454
Marey, H. M., Elmazar, H. F., Mandour, S. S., & Khairy, H. A. (2018). Combined Oral and Topical Beta Blockers for the Treatment of Early Proliferative Superficial Periocular Infantile Capillary Hemangioma. Journal of pediatric ophthalmology and strabismus, 55(1), 37–42. https://doi.org/10.3928/01913913-20170703-12
Gan, L. Q., Wang, H., Ni, S. L., & Tan, C. H. (2018). A prospective study of topical carteolol therapy in Chinese infants with superficial infantile hemangioma. Pediatric dermatology, 35(1), 121–125. https://doi.org/10.1111/pde.13361
Muñoz-Garza, F. Z., Ríos, M., Roé-Crespo, E., Bernabeu-Wittel, J., Montserrat-García, M. T., Puig, L., Gich, I., & Baselga, E. (2021). Efficacy and Safety of Topical Timolol for the Treatment of Infantile Hemangioma in the Early Proliferative Stage: A Randomized Clinical Trial. JAMA dermatology, 157(5), 583–587. https://doi.org/10.1001/jamadermatol.2021.0596
Li, C. X., Li, H., Zhou, Y. C., Gong, Z. C., & Ling, B. (2022). Application of topical betaxolol to cure superficial infantile hemangioma: A pilot study. Pediatrics international : official journal of the Japan Pediatric Society, 64(1), e15384. https://doi.org/10.1111/ped.15384
Downloads
Published
License
Copyright (c) 2023 RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218
This work is licensed under a Creative Commons Attribution 4.0 International License.
Os direitos autorais dos artigos/resenhas/TCCs publicados pertecem à revista RECIMA21, e seguem o padrão Creative Commons (CC BY 4.0), permitindo a cópia ou reprodução, desde que cite a fonte e respeite os direitos dos autores e contenham menção aos mesmos nos créditos. Toda e qualquer obra publicada na revista, seu conteúdo é de responsabilidade dos autores, cabendo a RECIMA21 apenas ser o veículo de divulgação, seguindo os padrões nacionais e internacionais de publicação.
